11.15.23 -- Building A Business Model For Novel Antibiotics

Optimizing the upstream portion of gene therapy production sets the stage for successful manufacturing by maximizing viral vector titers. To increase upstream titers and process productivity, manufacturers must partner with upstream technology experts who work with HEK293, HEK293T and Sf9 cells. Draw on our experience today to speed your gene therapy to patients. Learn more.

Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene therapy as well as achieving scalability with consistent yield and product purity in gene therapy manufacturing. Listen now and subscribe so you never miss an episode!

Throughout the pandemic, painkiller and sedative demands spiked. Drug manufacturers and CDMOs have become critical in efforts to stabilize the supply of Bupivacaine HCl and other essential drugs.

A successful drug commercialization effort requires meticulous planning, strategic thinking, and an integrated approach. Explore insights for successfully bringing new treatments to market.

Examine how an innovative formulation approach helped a developer create a version of their drug that promotes treatment compliance within the geriatric population.